Oncolytic virotherapy using coxsackie virus

Results of the Activ8 trial of novel immunotherapy motolimod

Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry

Comment: Ipilimumab in high risk stage III melanoma

Comment: Niraparib for ovarian cancer

Highlights of ESMO 2016

Promising results in metastatic bladder cancer using immunotherapy

Advances for NSCLC in review

Atezolizumab v docetaxel for NSCLC: results from the OAK trial

Significant survival gains with atezolizumab for NSCLC

Pembrolizumab plus chemo as firstline therapy for NSCLC

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients